G1 Therapeutics Provides Second Quarter 2020 Corporate and Financial Update
- Submitted New Drug Application (NDA) for trilaciclib in small cell lung cancer (SCLC)
- Co-promotion agreement with
- Partnership for trilaciclib in
- Increasing cash guidance for FY 2020 to
- Management to host webcast and conference call today at
“We made substantial progress on a number of fronts in the first half of 2020, and sharpened our focus on bringing trilaciclib to patients in 2021. By forging four strategic collaborations and securing a flexible credit facility, we have achieved three important objectives: positioning G1 for a strong commercial launch of trilaciclib in
Regulatory, Clinical and Corporate Highlights
- NDA for trilaciclib in small cell lung cancer (SCLC) submitted in
June 2020. Pending acceptance, the company expects to receive a PDUFA date assignment by the U.S. Food and Drug Administration(FDA) in August 2020. Trilaciclib has been assigned Breakthrough Therapy Designation by the FDA.
- Entered into co-promotion agreement with
Boehringer Ingelheimfor trilaciclib in SCLC in the United States and Puerto Rico. Under the terms of the three-year agreement, G1 and Boehringer Ingelheim will collaborate on the commercialization of trilaciclib for its first potential indication in SCLC. G1 will lead marketing, market access and medical engagement initiatives, with Boehringer Ingelheimleading sales force engagement initiatives. G1 will book revenue and retain development and commercialization rights to trilaciclib (press release here).
- Partnered with Simcere to develop and commercialize trilaciclib in
Greater China. The company entered into an exclusive agreement with Simcere Pharmaceuticals Groupfor the development and commercialization of trilaciclib for all indications in Greater China (mainland China, Hong Kong, Macau, and Taiwan). Under the terms of the agreement, G1 received a $14 millionupfront payment and is eligible to receive sales-based royalties and up to $156 millionin potential milestone payments (press release here). As part of this agreement, the company will collaborate with Simcere on future clinical trials. G1 and Simcere will be responsible for all development and commercialization costs in their respective territories.
- I-SPY 2 neoadjuvant breast cancer trial including trilaciclib initiated in 2Q20. Trilaciclib was selected for inclusion in the ongoing Phase 2 I-SPY 2 TRIAL™, based on compelling overall survival findings in a Phase 2 triple-negative breast cancer (TNBC) trial (press release here). The I-SPY trial will generate data across a range of breast cancer subtypes that will allow the company to evaluate trilaciclib in combination with several broadly-used chemotherapy classes and an anti-PD-1 immunotherapy.
- Rintodestrant and Ibrance combination trial initiated in 2Q20. The company previously announced preliminary safety, tolerability and efficacy data on rintodestrant, its oral selective estrogen receptor degrader (SERD) (press release here) as monotherapy treatment for ER+, HER2- breast cancer. Based on these findings, G1 initiated an additional arm of its ongoing Phase 1/2a trial to evaluate the combination regimen of rintodestrant and the CDK4/6 inhibitor Ibrance® (palbociclib). Palbociclib is being provided by Pfizer Inc. under a non-exclusive clinical supply agreement.
- Out-licensed global development and commercialization rights to lerociclib. The company entered into separate, exclusive agreements with EQRx (rights for
U.S., Europe, Japan, and all markets outside Asia-Pacific) and Genor Biopharma (rights for Asia-Pacific, excluding Japan) for the development and commercialization of lerociclib in all indications. Combined, these agreements provided $26 millionin upfront payments to G1, along with sales-based royalties and up to $330 millionin potential milestone payments (see press releases on EQRx agreement and Genor agreement). EQRx and Genor are responsible for all costs related to the development and commercialization of lerociclib in their respective territories.
- Out-licensed global development and commercialization rights to preclinical CDK2 inhibitor compounds. The company entered into an exclusive license agreement with ARC Therapeutics for global development and commercialization rights to its preclinical CDK2 inhibitor compounds. Under the terms of the agreement, G1 received an upfront payment and equity in ARC with an aggregate value of approximately
$2.1 million. The company is also entitled to receive an additional milestone payment and sales-based royalties, and has right of first negotiation to re-acquire these assets.
- Secured flexible credit financing for up to
$100 million. The company announced it had entered into a debt financing agreement for up to $100 million with Hercules Capital, Inc. G1 has accessed $20 millionto support the development and commercialization of trilaciclib (press release here).
Second Quarter 2020 Financial Highlights and 2020 Guidance
- Cash Position: Cash and cash equivalents totaled
$234.3 millionas of June 30, 2020, compared to $269.2 millionas of December 31, 2019.
- License Revenue: License revenues were
$2.1 millionfor the second quarter of 2020, related to the license of CDK2 inhibitor compounds to ARC Therapeutics.
- Operating Expenses: Operating expenses were
$33.0 millionfor the second quarter of 2020, compared to $32.6 millionfor the second quarter of 2019. GAAP operating expenses include stock-based compensation expense of $4.4 millionfor the second quarter of 2020, compared to $3.7 millionfor the second quarter of 2019.
- Research and Development Expenses: Research and development (R&D) expenses for the second quarter of 2020 were
$18.5 million, compared to $23.5 millionfor the second quarter of 2019. The decrease in R&D expenses was primarily due to a decrease in clinical program costs of $3.4 millionand regulatory filing reimbursement received during the second quarter of 2020 for $3.0 million, offset by an increase in costs for manufacturing active pharmaceutical ingredients.
- General and Administrative Expenses: General and administrative (G&A) expenses for the second quarter of 2020 were
$14.4 million, compared to $9.1 millionfor the second quarter of 2019. The increase in G&A expenses was largely due to an increase in compensation due to additional headcount, increase in pre-commercialization activities, increase in medical affairs costs, and an increase in professional fees and other administrative costs necessary to support our operations.
- Net Loss: G1 reported a net loss of
$31.2 millionfor the second quarter of 2020, compared to $30.7 millionfor the second quarter of 2019.
- 2020 Guidance: The company is increasing its previous financial guidance and expects to end 2020 with
$185-$200 millionin cash and cash equivalents, up from previous guidance of $110-$130 million. This guidance includes receipt of upfront payments from recent agreements, but does not include consideration of potential additional proceeds from partnerships, collaboration activities, and/or other sources of capital.
Key Anticipated 2020 Milestones
- NDA acceptance/PDUFA date assignment for trilaciclib in SCLC in
- Initiate Phase 3 clinical trial of trilaciclib in colorectal cancer in 4Q20.
- Presentation of Phase 2 data of trilaciclib in triple-negative breast cancer in 4Q20.
- Presentation of additional rintodestrant monotherapy data in 4Q20.
Webcast and Conference Call
The management team will host a webcast and conference call at
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this press release include, but are not limited to, those relating to the therapeutic potential of trilaciclib, rintodestrant and lerociclib, the timing of marketing applications in the
Senior Director, Investor Relations & Corporate Communications
Balance Sheet Data
|Cash and cash equivalents||$||234,267||$||269,208|
|Total stockholders’ equity||$||203,845||$||255,527|
Condensed Statements of Operations
(in thousands, except per share data)
|Three Months Ended
|| Six Months Ended
|License revenue – related party||$||2,140||$||—||$||2,140||$||—|
|Research and development||18,531||23,489||38,965||41,569|
|General and administrative||14,431||9,094||25,818||16,896|
|Total operating expenses||32,962||32,583||64,783||58,465|
|Loss from operations||(30,822)||(32,583)||(62,643)||(58,465)|
|Other income (expense):|
|Other income (expense)||(214)||—||(197)||14|
|Total other income (expense), net||(388)||1,893||410||3,823|
|Net loss per share, basic and diluted||$||(0.83)||$||(0.82)||$||(1.65)||$||(1.46)|
|Weighted average common shares outstanding, basic and diluted||37,786,208||37,470,926||37,722,965||37,434,156|
Source: G1 Therapeutics